0001867287
false
00-0000000
NY
0001867287
2023-07-11
2023-07-11
0001867287
LBBB:OrdinarySharesMember
2023-07-11
2023-07-11
0001867287
LBBB:WarrantsMember
2023-07-11
2023-07-11
0001867287
us-gaap:RightsMember
2023-07-11
2023-07-11
0001867287
LBBB:UnitsMember
2023-07-11
2023-07-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
July 11, 2023
Date of Report (Date of earliest event reported)
Lakeshore Acquisition II Corp.
(Exact Name of Registrant as Specified in its Charter)
Cayman Islands |
|
001-41317 |
|
N/A |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.) |
667 Madison Avenue,
New York, NY |
|
10065 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (917) 327-9933
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☒ |
Written communications pursuant to Rule 425 under the Securities Act |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Ordinary Shares |
|
LBBB |
|
The Nasdaq Stock Market LLC |
Warrants |
|
LBBBW |
|
The Nasdaq Stock Market LLC |
Rights |
|
LBBBR |
|
The Nasdaq Stock Market LLC |
Units |
|
LBBBU |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
IMPORTANT NOTICES
Important Notice Regarding Forward-Looking
Statements
This Current Report on Form 8-K contains
certain “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934,
both as amended. Statements that are not historical facts, including statements about the pending transactions among Lakeshore Acquisition
II Corp. (together with its successors, the “Purchaser”), LBBB Merger Sub Inc., a Delaware corporation and wholly-owned
subsidiary of Purchaser (the “Merger Sub”), Nature’s Miracle Inc., a Delaware corporation (“Nature’s
Miracle”), Tie (James) Li, as the representative of the stockholders of Nature’s Miracle, and RedOne Investment Limited,
a British Virgin Islands company, as the representative of the shareholders of Purchaser, and the transactions contemplated thereby, and
the parties’ perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements
regarding the proposed transaction, including the anticipated initial enterprise value and post-closing equity value, the benefits of
the proposed transaction, integration plans, expected synergies and revenue opportunities, anticipated future financial and operating
performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected
timing of the transactions. The words “expect,” “believe,” “estimate,” “intend,” “plan”
and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance
and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational
factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.
Such risks and uncertainties include, but are
not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the
price of Purchaser’s securities; (ii) the risk that the transaction may not be completed by Purchaser’s business combination
deadline and the potential failure to obtain an extension of the business combination deadline if sought by Purchaser; (iii) the
failure to satisfy the conditions to the consummation of the transaction, including the approval of the business combination agreement
by the stockholders of Purchaser, the satisfaction of the minimum cash amount following any redemptions by Purchaser’s public stockholders
and the receipt of certain governmental and regulatory approvals; (iv) the lack of a third-party valuation in determining whether
or not to pursue the proposed transaction; (v) the occurrence of any event, change or other circumstance that could give rise to
the termination of the business combination agreement; (vi) the effect of the announcement or pendency of the transaction on Nature’s
Miracle’s business relationships, operating results and business generally; (vii) risks that the proposed transaction disrupts
current plans and operations of Nature’s Miracle; (viii) the outcome of any legal proceedings that may be instituted against
Nature’s Miracle or Purchaser related to the business combination agreement or the proposed transaction; (ix) the ability to
maintain the listing of Purchaser’s securities on a national securities exchange; (x) changes in the competitive industry in
which Nature’s Miracle operates, variations in operating performance across competitors, changes in laws and regulations affecting
Nature’s Miracle’s business and changes in the combined capital structure; (xi) the ability to implement business plans,
forecasts and other expectations after the completion of the proposed transaction, and identify and realize additional opportunities;
(xii) the risk of downturns in the market and Nature’s Miracle’s industry including, but not limited to, as a result
of the COVID-19 pandemic; (xiii) costs related to the transaction and the failure to realize anticipated benefits of the transaction
or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions; (xiv) the
inability to complete its convertible debt financing; (xv) the risk of potential future significant dilution to stockholders resulting
from lender conversions under the convertible debt financing; and (xvi) risks and uncertainties related to Nature’s Miracle’s
business, including, but not limited to, risks relating to the uncertainty of the projected financial information with respect to Nature’s
Miracle; risks related to Nature’s Miracle’s limited operating history, the roll-out of Nature’s Miracle’s business
and the timing of expected business milestones; Nature’s Miracle’s ability to implement its business plan and scale its business;
Nature’s Miracle’s ability to develop products and technologies that are more effective or commercially attractive than competitors’
products; Nature’s Miracle’s ability to maintain accelerate rate of growth recently due to lifestyle changes in the wake of
COVID-19 pandemic; risks of increased costs as a result of being a public company; risks relating to Nature’s Miracle’s being
unable to renew the leases of their facilities and warehouses; Nature’s Miracle’s ability to grow the size of its organization
and management in response of the increase of sales and marketing infrastructure; risks relating to potential tariffs or a global trade
war that could increase the cost of Nature’s Miracle’s products; risks relating to product liability lawsuits that could be
brought against Nature’s Miracle;; Nature’s Miracle’s ability to formulate, implement and modify as necessary effective
sales, marketing, and strategic initiatives to drive revenue growth; Nature’s Miracle’s ability to expand internationally;
acceptance by the marketplace of the products and services that Nature’s Miracle markets; and government regulations and Nature’s
Miracle’s ability to obtain applicable regulatory approvals and comply with government regulations. A further list and description
of risks and uncertainties can be found in Purchaser’s initial public offering prospectus dated March 8, 2022 and in the Registration
Statement on Form S-4 and proxy statement initially filed with the Securities and Exchange Commission (“SEC”) on November
14, 2022 (as amended and as may be further amended) by the Purchaser in connection with the proposed transactions, and other documents
that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated
by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking
statements relate only to the date they were made, and Purchaser, Merger Sub, Nature’s Miracle, and their subsidiaries undertake
no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required
by law or applicable regulation.
Additional Information and Where to Find It
In connection with the proposed business combination,
Purchaser has filed relevant materials with the SEC, including the Registration Statement on Form S-4 and a proxy statement. The
proxy statement and a proxy card will be mailed to shareholders as of a record date to be established for voting at the shareholders’
meeting relating to the proposed transactions. Shareholders will also be able to obtain a copy of the Registration Statement on Form S-4
and proxy statement without charge from Purchaser. The Registration Statement on Form S-4 and proxy statement, as available, may
also be obtained without charge at the SEC’s website at www.sec.gov or by writing to Purchaser at 667 Madison Avenue, New York,
NY 10065.
INVESTORS AND SECURITY HOLDERS OF PURCHASER
ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH
THE TRANSACTIONS THAT PURCHASER WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT
PURCHASER, NATURE’S MIRACLE AND THE TRANSACTIONS.
Participants in Solicitation
Purchaser, Merger Sub, Nature’s Miracle,
certain stockholders of Nature’s Miracle, and their respective directors, executive officers and employees and other persons may
be deemed to be participants in the solicitation of proxies from the holders of Purchaser ordinary shares in respect of the proposed transaction.
Information about Purchaser’s directors and executive officers and their ownership of Purchaser’s ordinary shares is set forth
in Purchaser’s initial public offering prospectus dated March 8, 2022 and other filings by the Purchaser filed with the SEC.
Other information regarding the interests of the participants in the proxy solicitation will be included in the proxy statement pertaining
to the proposed transaction when it becomes available. These documents can be obtained free of charge from the sources indicated above.
No Offer or Solicitation
This Current Report on Form 8-K is not
a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential business
combination or any other matter and will not constitute an offer to sell or a solicitation of an offer to buy the securities of Purchaser,
Nature’s Miracle or the combined company, nor will there be any sale of any such securities in any state or jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or
jurisdiction. No offer of securities will be made except by means of a prospectus meeting the requirements of the Securities Act of 1933,
as amended.
Item 1.01 Entry into a Material definitive Agreement.
The disclosure contained in Item 2.03 is incorporated by reference
in this Item 1.01.
Item 2.03 Creation of a Direct Financial Obligation
or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
On July 11, 2023, Lakeshore Acquisition II Corp.,
a Cayman Islands exempted company (together with its successors, the “Company”) entered into two separate loan agreements
for an aggregate principal amount of $250,000, on substantially the same terms. The lender of the first loan agreement is Bill Chen, Chief
Executive Officer of the Company, who agreed to lend the Company a principal amount of $125,000, and the lender of the second loan agreement
is James Li, the Chief Executive Officer of Nature’s Miracle, Inc., the target in the previously announced proposed business combination
with the Company, who agreed to lend the Company a principal amount of $125,000.
Pursuant to the loan agreements, the loans are
unsecured and do not bear interest; provided that, if the loan is not repaid by the maturity date on November 11, 2023, then the outstanding
amount will bear interest at 8% per annum, and will be payable with accrued interest on demand.
The loans closed on July 12, 2023. The proceeds
of the loans have been used to repay in full the Company’s previously disclosed $250,000 loan pursuant to the loan agreement, dated
March 10, 2023, by and between the Company, the lender named therein, and RedOne Investment Limited, the Company’s sponsor, and
Nature’s Miracle, as guarantors.
The loan agreements also provide for the issuance
to each lender of 12,500 shares of Class A common stock (or 25,000 shares in the aggregate) of the post-business combination company no
later than the earlier of (i) the maturity date and (ii) the closing of the planned business combination between the Company and Nature’s
Miracle. The loan agreements also provide for customary registration rights for such shares.
The foregoing description is qualified in its
entirety by reference to the loan agreements, a form of which is attached as Exhibit 10.1 hereto and is incorporated herein by reference.
Item 3.02 Unregistered Sales of Equity Securities.
The information set forth above in Item 2.03 of
this Report is incorporated by reference herein. The shares of Class A common stock are being issued and sold by the Company to each of
the lenders, or their designees, in reliance upon the exemption from the registration requirements of the Securities Act afforded by Section
4(a)(2) of the Securities Act.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits:
Exhibit No. |
|
Description |
10.1 |
|
Form of Loan Agreement. |
104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 12, 2023
LAKESHORE ACQUISITION II CORP.
By: |
/s/ Deyin (Bill) Chen |
|
Name: |
Deyin (Bill) Chen |
|
Title: |
Chief Executive Officer |
|
4
Exhibit 10.1
Form of Loan Agreement
This Loan Agreement (this
“Agreement”) is made as of this 11th day of July, 2023 by and between [_] (“Lender”) and Lakeshore
Acquisition II Corp., a Cayman Islands exempted company (“SPAC” and/or “Borrower”).
WHEREAS, SPAC was organized for the purpose of
acquiring, through a merger, capital stock exchange, asset acquisition or other similar business combination, an operating business; and
WHEREAS Nature’s Miracle,
Inc., a Delaware corporation (“NMI”); has entered into a merger agreement on September 9, 2022 with the SPAC;
WHEREAS, SPAC, and the other
parties named therein entered into a merger agreement and plan of merger dated September 9, 2022 (the “Acquisition Agreement”),
pursuant to which, among other things, SPAC will reincorporate to the State of Delaware (the “Reincorporation”); and
(ii) immediately after the Reincorporation, LBBB Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of PubCo (“Merger
Sub”), will be merged with and into NMI, with NMI surviving as a wholly-owned subsidiary of Merger Sub (the “Merger”);
and
WHEREAS, the proposed business
combination is expected to be completed by or before October 11, 2023.
NOW, THEREFORE, in consideration
of the mutual covenants hereinafter set forth and other good and valuable consideration, the sufficiency of which is hereby acknowledged,
the parties hereby agree as follows.
ARTICLE I
DEFINITIONS
Section 1. Definitions. In
addition to the other terms defined herein, the following terms used herein shall have the meanings herein specified (to be equally applicable
to both the singular and plural forms of the terms defined).
Section 1.01. Lending.
Subject to the terms and conditions of this Agreement, “Lending” shall mean Lender’s promise to lend to Borrower
a sum of $125,000.00 US Dollars on the condition that the aforementioned business combination will occur.
Section 1.02. Loan or Principal Amount. “Loan” or “Principal Amount”
shall mean the sum of $125,000.00 U.S. Dollars.
Section 1.03. Closing. “Closing”
shall mean July 11, 2023, 4:00pm ET.
Section 1.04. Merger Date.
“Merger Date” shall mean the date when Lakeshore Acquisition II Corp. and Nature’s Miracle, Inc. have officially
completed their merger.
Section 1.05. Applicable
Interest Rate. “Applicable Interest Rate” shall mean 8% per annum.
Section 1.06. Repayment Date. “Repayment Date”
shall mean November 11, 2023.
Section 1.07. Bonus Shares.
“Bonus Shares” shall mean 12,500 shares of the company that survives after Merger Date, and said Shares should be registered
through S-1 filing with SEC immediately after the Merger closing.
Section 1.08. Bank Account.
“Bank Account” shall mean the bank account described in Exhibit “A.”
ARTICLE II
Amount
and terms of lending
Section 2.01. Lending.
Lender shall make the Loan to Borrower on Closing; provided that [(i) ]SPAC proceeds with the proposed merger as described in the Acquisition
Agreement dated September 9, 2022[, and (ii) Deyin Chen (Bill) shall have made a loan of $125,000.00 US Dollars to the Borrower on substantially
the same terms as this Agreement on or before Closing]1.
The Loan shall be wired to the Bank Account.
Section 2.02. Repayment.
Borrower shall pay Lender the Principal Amount on or before Repayment Date. Borrower acknowledges and agrees, however, that, if, for any
reason, Lender does not receive the full amount of Principal Amount by Repayment Date, the outstanding and unpaid Principal Amount, shall
bear interest at the Applicable Interest Rate, and shall be payable, with accrued interest, ON DEMAND.
Section 2.03. Bonus Shares.
Borrower shall cause the new company that survives after the Merger pursuant to the Acquisition Agreement to issue Bonus Shares to Lender
or its nominee no later than the Repayment Date or the Merger Date, whichever is earlier. All Bonus Shares must be registered under Lender’s
or its nominee’s business name.
ARTICLE III
Representations,
Warranties And Covenants of the Borrower
Borrower hereby represents
and warrants to Lender on the date hereof and as of the Closing that:
Section 3.01 Organization.
Borrower has the legal authority to execute, deliver and carry out the terms of this Agreement and to consummate the transactions contemplated
hereby.
| 1 | The loan agreement with James Li includes a condition that Bill
Chen shall have made the loan of $125,000 to the Borrower, which condition is not applicable to the loan agreement with Bill Chen. |
Section 3.02 Authority;
Non-Contravention. This Agreement has been validly authorized, executed and delivered by Borrower and, assuming the due authorization,
execution and delivery thereof by Lender, is a valid and binding agreement enforceable in accordance with its terms, subject to the general
principles of equity and to bankruptcy or other laws affecting the enforcement of creditors’ rights generally. The execution, delivery
and performance of this Agreement by Borrower does not and will not conflict with, violate or cause a breach of, constitute a default
under, or result in a violation of (i) any agreement, contract or instrument to which Borrower is a party which would prevent Borrower from performing its obligations hereunder or (ii) any law, statute, rule or regulation to which
Borrower is subject.
Section 3.03 No Legal Advice
from Lender. Borrower acknowledges it has had the opportunity to review this Agreement and the transactions contemplated by this Agreement
with Borrower’s own legal counsel, investment and tax advisors. Borrower is not relying on any statements or representations of
Lender or any of its representatives or agents for legal, tax or investment advice with respect to this Agreement or the transactions
contemplated by the Agreement.
ARTICLE IV
Representations
and Warranties of the Lender
Lender hereby represents and warrants to Borrower on the date hereof
and as of the Closing that:
Section 4.01 Organization.
Lender has the legal authority to execute, deliver and carry out the terms of this Agreement and to consummate the transactions contemplated
hereby.
Section 4.02 Authority;
Non-Contravention. This Agreement is validly authorized, executed and delivered by Lender and assuming the due authorization,
execution and delivery thereof by Borrower, is a valid and binding agreement enforceable in accordance with its terms, subject to
the general principles of equity and to bankruptcy or other laws affecting the enforcement of creditors’ rights generally. The
execution, delivery and performance of this Agreement by Lender does not and will not conflict with, violate or cause a breach of,
constitute a default under, or result in a violation of (i) any agreement, contract or instrument to which Lender is a party which
would prevent Lender from performing its obligations hereunder or (ii) any law, statute, rule or regulation to which Lender is
subject.
Section 4.03 Governmental
Approvals. All consents, approvals, orders, authorizations, registrations, qualifications, designations, declarations or filings with
any governmental or other authority on the part of Lender required in connection with the consummation of the transactions contemplated
in the Agreement have been or shall have been obtained prior to and be effective as of the Closing.
ARTICLE V
TRUST WAIVER
Section 5.01. Trust Waiver.
The Lender has been provided a copy of the SPAC’s initial public offering (the “IPO”) prospectus dated March 8, 2022
(the “Prospectus”). Notwithstanding anything herein to the contrary, the Lender hereby waives any and all right, title, interest
or claim of any kind (“Claim”) in or to any amounts contained in the trust account in which the proceeds of the IPO conducted
by the SPAC and the proceeds of the sale of securities in a private placement that occurred prior to the effectiveness of the IPO, as
described in greater detail in the Prospectus, were placed, and hereby agrees not to seek recourse, reimbursement, payment or satisfaction
for any Claim from the trust account or any distribution therefrom for any reason whatsoever. If the SPAC does not consummate a business
combination, the Loan shall be repaid only from amounts remaining outside of the trust account, if any.
ARTICLE
VI
Miscellaneous
Section 6.01 Disclosure.
Notwithstanding anything in this Agreement to the contrary, the Borrower and SPAC shall not publicly disclose the name of Lender or
any of its affiliates, or include the name of the Lender or any of its affiliates in any press release or in any filing with the Securities
and Exchange Commission (the “Commission”) or any regulatory agency or trading market, without the prior written consent of
the Lender, except (i) as required by the federal securities laws, and (ii) to the extent such disclosure is required by law, at the request
of the staff of the Commission or regulatory agency or under the regulations of Nasdaq, in which case the Borrower and SPAC shall provide
the Lender with prior written notice of such disclosure, and shall reasonably consult with the Lender regarding such disclosure.
Section 6.02 Counterparts;
Facsimile. This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original
and all of which taken together shall constitute one and the same instrument. This Agreement or any counterpart may be executed via facsimile
transmission or scanned copy, and any such executed facsimile or scanned copy shall be treated as an original.
Section 6.03 Governing
Law. This Agreement shall for all purposes be deemed to be made under and shall be construed in accordance with the laws of State
of New York.
Section 6.04. Venue.
The venue for any action taken with respect to this Agreement shall be any state or federal court in New York County in the State of New
York.
Section 6.05 Remedies Cumulative.
Each of the parties hereto acknowledges and agrees that, in the event of any breach of any covenant or agreement contained in this Agreement
by the other party, money damages may be inadequate with respect to any such breach and the non-breaching party may have no adequate remedy
at law. It is accordingly agreed that each of the parties hereto shall be entitled, in addition to any other remedy to which they may
be entitled at law or in equity, to seek injunctive relief and/or to compel specific performance to prevent breaches by the other party
hereto of any covenant or agreement of such other party contained in this Agreement. Accordingly, Borrower and SPAC
hereby agree that Lender is entitled to an injunction prohibiting any conduct by the Borrower or SPAC in violation of this Agreement and
Borrower and SPAC shall not seek the posting of any bond in connection with such request for an injunction. Furthermore, in any action
by Lender to enforce this Agreement, Borrower and SPAC waive their right to assert any counterclaims and its right to assert set-off as
a defense. The prevailing party agrees to pay all costs and expenses, including reasonable attorneys’ and experts’ fees that such prevailing
party may incur in connection with the enforcement of this Agreement.
Section 6.06 Severability.
If any term, provision or covenant of this Agreement is held by a court of competent jurisdiction or other authority to be invalid, void
or unenforceable, the remainder of the terms, provisions and covenants of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.
Section 6.07 Binding Effect;
Assignment. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective legal representatives,
successors and permitted assigns.
Section 6.08 Headings.
The descriptive headings of the Sections hereof are inserted for convenience only and do not constitute a part of this Agreement.
Section 6.09 Entire Agreement;
Changes in Writing. This Agreement constitutes the entire agreement among the parties hereto and supersedes and cancels any prior
agreements, representations and warranties, whether oral or written, among the parties hereto relating to the transaction contemplated
hereby. Neither this Agreement nor any provision hereof may be changed or amended orally, but only by an agreement in writing signed by
the other party hereto.
[Signature Page Follows]
IN WITNESS WHEREOF, the undersigned have executed
this Agreement as of the date set forth on the first page of this Agreement.
|
Lender: [_] |
|
|
|
By: |
|
|
Name: |
|
|
Email: |
|
|
|
|
Borrower: LAKESHORE ACQUISITION II
CORP. |
|
|
|
By: |
|
|
Name: |
Bill Chen |
|
Title: |
Chief Executive Officer |
Exhibit A
Wiring Instructions
v3.23.2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=LBBB_OrdinarySharesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=LBBB_WarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_RightsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=LBBB_UnitsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Lakeshore Acquisition II (NASDAQ:LBBBU)
Historical Stock Chart
From Sep 2024 to Oct 2024
Lakeshore Acquisition II (NASDAQ:LBBBU)
Historical Stock Chart
From Oct 2023 to Oct 2024